Galena Biopharma (GALE) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Galena Biopharma Reports Second Quarter 2015 Financial Results
August 6, 2015 4:10 PM EDTCompleted over-enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial and presented encouraging data for GALE-301 and GALE-401 programs Achieved net revenue of $3.4 million for Q2, totaling $6.1 million for 1H, 2015 from Abstral® (fentanyl) Sublingual Tablets; Launched Zuplenz® (ondansetron) Oral Soluble Film in the U.S. on July 29, 2015. Projected full year 2015 net revenue guidance of approximately $15 million Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T.
PORTLAND, Ore., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:... More
